These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

562 related articles for article (PubMed ID: 15233869)

  • 1. Effects of monensin liposomes on the cytotoxicity, apoptosis and expression of multidrug resistance genes in doxorubicin-resistant human breast tumour (MCF-7/dox) cell-line.
    Shaik MS; Chatterjee A; Singh M
    J Pharm Pharmacol; 2004 Jul; 56(7):899-907. PubMed ID: 15233869
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Resveratrol enhances chemosensitivity of doxorubicin in multidrug-resistant human breast cancer cells via increased cellular influx of doxorubicin.
    Kim TH; Shin YJ; Won AJ; Lee BM; Choi WS; Jung JH; Chung HY; Kim HS
    Biochim Biophys Acta; 2014 Jan; 1840(1):615-25. PubMed ID: 24161697
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Vielanin P enhances the cytotoxicity of doxorubicin via the inhibition of PI3K/Nrf2-stimulated MRP1 expression in MCF-7 and K562 DOX-resistant cell lines.
    Gao HL; Xia YZ; Zhang YL; Yang L; Kong LY
    Phytomedicine; 2019 May; 58():152885. PubMed ID: 31009836
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reversal effect of isotetrandrine, an isoquinoline alkaloid extracted from Caulis Mahoniae, on P-glycoprotein-mediated doxorubicin-resistance in human breast cancer (MCF-7/DOX) cells.
    Wang TX; Yang XH
    Yao Xue Xue Bao; 2008 May; 43(5):461-6. PubMed ID: 18717331
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Development of rational in vitro models for drug resistance in breast cancer and modulation of MDR by selected compounds.
    Kars MD; Iseri OD; Gündüz U; Ural AU; Arpaci F; Molnár J
    Anticancer Res; 2006; 26(6B):4559-68. PubMed ID: 17201178
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of MDR modulators verapamil and promethazine on gene expression levels of MDR1 and MRP1 in doxorubicin-resistant MCF-7 cells.
    Dönmez Y; Akhmetova L; İşeri ÖD; Kars MD; Gündüz U
    Cancer Chemother Pharmacol; 2011 Apr; 67(4):823-8. PubMed ID: 20563580
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A P-glycoprotein- and MRP1-independent doxorubicin-resistant variant of the MCF-7 breast cancer cell line with defects in caspase-6, -7, -8, -9 and -10 activation pathways.
    Park SJ; Wu CH; Safa AR
    Anticancer Res; 2004; 24(1):123-31. PubMed ID: 15015586
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Induction of multidrug resistance in MOLT-4 cells by anticancer agents is closely related to increased expression of functional P-glycoprotein and MDR1 mRNA.
    Liu ZL; Onda K; Tanaka S; Toma T; Hirano T; Oka K
    Cancer Chemother Pharmacol; 2002 May; 49(5):391-7. PubMed ID: 11976833
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reversal of multidrug resistance by guggulsterone in drug-resistant MCF-7 cell lines.
    Xu HB; Li L; Liu GQ
    Chemotherapy; 2011; 57(1):62-70. PubMed ID: 21282948
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sensitization of multidrug-resistant malignant cells by liposomes co-encapsulating doxorubicin and chloroquine through autophagic inhibition.
    Gao M; Xu Y; Qiu L
    J Liposome Res; 2017 Jun; 27(2):151-160. PubMed ID: 27250110
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Reversion of multidrug resistance in a chemoresistant human breast cancer cell line by β-elemene.
    Xu HB; Li L; Fu J; Mao XP; Xu LZ
    Pharmacology; 2012; 89(5-6):303-12. PubMed ID: 22573000
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reversal of P-glycoprotein-mediated multidrug resistance of cancer cells by five schizandrins isolated from the Chinese herb Fructus Schizandrae.
    Huang M; Jin J; Sun H; Liu GT
    Cancer Chemother Pharmacol; 2008 Nov; 62(6):1015-26. PubMed ID: 18270702
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of doxorubicin on telomerase activity and apoptotic gene expression in doxorubicin-resistant and -sensitive MCF-7 cells: an experimental study.
    Eskiocak U; Işeri OD; Kars MD; Biçer A; Gunduz U
    Chemotherapy; 2008; 54(3):209-16. PubMed ID: 18560228
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Schisandrin A reverses doxorubicin-resistant human breast cancer cell line by the inhibition of P65 and Stat3 phosphorylation.
    Zhang ZL; Jiang QC; Wang SR
    Breast Cancer; 2018 Mar; 25(2):233-242. PubMed ID: 29181822
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Reversal effect of haloperidol on doxorubicin resistance and chloride channel inhibition in erythroleukemic cell K562/Dox].
    Zhou JH; Wu DZ
    Zhonghua Zhong Liu Za Zhi; 2005 Feb; 27(2):81-5. PubMed ID: 15946544
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reversal of cancer multidrug resistance by green tea polyphenols.
    Mei Y; Qian F; Wei D; Liu J
    J Pharm Pharmacol; 2004 Oct; 56(10):1307-14. PubMed ID: 15482646
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reversal of doxorubicin resistance by guggulsterone of Commiphora mukul in vivo.
    Xu HB; Shen ZL; Fu J; Xu LZ
    Phytomedicine; 2014 Sep; 21(11):1221-9. PubMed ID: 25172783
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Salinomycin enhances doxorubicin-induced cytotoxicity in multidrug resistant MCF-7/MDR human breast cancer cells via decreased efflux of doxorubicin.
    Kim KY; Kim SH; Yu SN; Park SK; Choi HD; Yu HS; Ji JH; Seo YK; Ahn SC
    Mol Med Rep; 2015 Aug; 12(2):1898-904. PubMed ID: 25892525
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pegylated phosphotidylethanolamine inhibiting P-glycoprotein expression and enhancing retention of doxorubicin in MCF7/ADR cells.
    Wang J; Qu H; Jin L; Zeng W; Qin L; Zhang F; Wei X; Lu W; Zhang C; Liang W
    J Pharm Sci; 2011 Jun; 100(6):2267-77. PubMed ID: 21246559
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting P-glycoprotein function, p53 and energy metabolism: Combination of metformin and 2-deoxyglucose reverses the multidrug resistance of MCF-7/Dox cells to doxorubicin.
    Xue C; Wang C; Sun Y; Meng Q; Liu Z; Huo X; Sun P; Sun H; Ma X; Ma X; Peng J; Liu K
    Oncotarget; 2017 Jan; 8(5):8622-8632. PubMed ID: 28052008
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 29.